Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company, founded in 1994 and headquartered in Lexington, MA, aims to expand patient populations benefiting from cancer immunotherapy through combination approaches. Agenus utilizes a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics), and adjuvants (through SaponiQx). The company received a significant $40.00M Post-IPO Equity investment on 11 October 2018. Agenus' mission to contribute to the field of biotechnology by focusing on immunological solutions for cancer and infectious diseases is noteworthy. For further information regarding Agenus, please visit their website at www.agenusbio.com or follow them at @agenus_bio. Additionally, the company's Community Guidelines are available at their website and at: https://agenusbio.com/community-guidelines/.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $75.00M | 1 | Ligand Pharmaceuticals | 07 May 2024 |
| Post-IPO Equity | $40.00M | - | 11 Oct 2018 | |
| Post-IPO Equity | $60.00M | 1 |
|
14 Feb 2017 |
| Post-IPO Debt | $100.00M | - | 23 Sep 2015 | |
| Post-IPO Equity | $35.00M | - | 11 Mar 2015 |
No recent news or press coverage available for Agenus.
We care about your data, and we'd love to use cookies make your experience better.
